Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H15NO2 |
Molecular Weight | 181.2316 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNCC(O)C1=CC=CC(O)=C1
InChI
InChIKey=SQVIAVUSQAWMKL-UHFFFAOYSA-N
InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
Molecular Formula | C10H15NO2 |
Molecular Weight | 181.2316 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.sopharma.com/etilefrine.phpCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/26240886
https://en.wikipedia.org/wiki/Etilefrin
Sources: https://www.sopharma.com/etilefrine.php
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/26240886
https://en.wikipedia.org/wiki/Etilefrin
Etilefrine is a cardiac stimulant used as an antihypotensive. Intravenous infusion of this compound increases cardiac output, stroke volume, venous return and blood pressure in man and experimental animals, suggesting stimulation of both α and β adrenergic receptors. However, in vitro studies indicate that etilefrine has a much higher affinity for β1 (cardiac) than for β2 adrenoreceptors. Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, central venous pressure and mean arterial pressure of healthy individuals. Marked falls in pulse rate, cardiac output, stroke volume and peripheral bloodflow, accompanied by rises in mean arterial pressure, occur when etilefrine is infused after administration of intravenous propranolol 2,5 mg. These findings indicate that etilefrine has both β1 and α1 adrenergic effects in man. The French Health Products Agency concluded that etilefrine and heptaminol have an unfavourable harm-benefit balance, and also placed restrictions on the use of midodrine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4790080 |
|||
Target ID: CHEMBL213 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4790080 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/12181066 |
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of selected drugs on arterial pressure response to upright posture. | 1976 |
|
Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. | 1989 Nov |
|
Etilefrine in the prevention of prolonged erection after diagnostic pharmacological stimulation. | 1996 |
|
[Ambulatory treatment and prevention of priapism using alpha-agonists. Apropos of 172 cases]. | 1997 Jan |
|
[Management of priapism in sickle-cell diseases with alpha-adrenergic agonists]. | 2002 Jul-Sep |
|
Management of thoracic duct injuries after oesophagectomy (Br J Surg 2001: 88: 1442-8). Letter 1. | 2002 Jun |
|
Etilefrine use in the management of post-operative chyle leaks in thoracic surgery. | 2004 Mar |
|
[A patient with Shy-Drager syndrome managed under general anesthesia with thoracic epidural anesthesia]. | 2005 Jul |
|
Effects of cafedrine/theodrenaline, etilefrine and ephedrine on uterine blood flow during epidural-induced hypotension in pregnant sheep. | 2005 Sep-Oct |
|
Dissociation between cortical activation and cognitive performance under pharmacological blood pressure elevation in chronic hypotension. | 2007 Jul |
|
Stuttering priapism--a review of the therapeutic options. | 2008 Aug |
|
Chylous ascites following radical nephrectomy: a case report. | 2008 Jan 11 |
|
Effect of systemic blood pressure on microcollateral circulation evaluated by real-time contrast echocardiography. | 2008 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10758467
15 mg (30 drops)
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:20:22 GMT 2023
by
admin
on
Fri Dec 15 16:20:22 GMT 2023
|
Record UNII |
ZB6F8MY53V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01CA51
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
||
|
WHO-VATC |
QC01CA01
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/02/122
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
||
|
NCI_THESAURUS |
C29747
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
||
|
WHO-ATC |
C01CA01
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
||
|
WHO-ATC |
C01CA51
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1101
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
2229
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL86882
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
C65576
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
10128-36-6
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
SUPERSEDED | |||
|
DB08985
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
SUB07303MIG
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
m5184
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
2409-85-0
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
SUPERSEDED | |||
|
4169
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | RxNorm | ||
|
Etilefrine
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
D005039
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
ZB6F8MY53V
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
DTXSID1023029
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
100000082095
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
233-359-9
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
ALTERNATIVE | |||
|
211-910-4
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
709-55-7
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY | |||
|
3306
Created by
admin on Fri Dec 15 16:20:22 GMT 2023 , Edited by admin on Fri Dec 15 16:20:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |